ABOS · Acumen Pharmaceuticals Inc
United States · RS rating 15 · As of 2026-10-14
| Price | 1.75 USD |
|---|---|
| 1-day change | -3.9% |
| RS rating (overall / 1M / 3M / 12M) | 15 / 4 / 20 / 27 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 21 / 19 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -36.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +48.2% |
| Market cap (USD) | $192.8M |